Platelet-derived growth factor levels in wounds of diabetic rats

doi:10.1016/0024-3205(95)02056-O

Life Sciences

Volume 57, Issue 11, 4 August 1995, Pages 1111-1123

https://doi.org/10.1016/0024-3205(95)02056-O Get rights and content

Abstract

Delayed wound healing is a troublesome complication of Diabetes. Results from recent investigations concerning the potential cellular and molecular mechanisms responsible for diabetic wound healing deficiency are preliminary in nature. Some studies have demonstrated that direct application of certain growth factors/cytokines can facilitate wound healing in diabetic models. It is possible that refractory diabetic wounds are the result of deficiencies in growth factors/cytokines important for the normal wound healing process. Platelet-Derived Growth Factor (PDGF) levels were examined by radioimmunoassay in wound tissue of normal and diabetic rats (streptozotocin-induced diabetes). Immunohistochemical analysis was utilized to localize and characterize PDGF immunopositive cells at the wound site of normal and diabetic animals. At the wound site, normal animals demonstrated significantly elevated PDGF levels compared to diabetic animals at 5 days post-wounding (no differences were observed in the spleen or contralateral control tissue). There appeared to be a visible increase in PDGF immunopositive cells at the wound site in both experimental and control groups. By day 10 post-wounding, PDGF levels at the wound site in normal animals were reduced becoming similar to PDGF levels in diabetic animals. This corresponded to an apparent reduction of PDGF immunopositive cells in both groups (similar to baseline levels). PDGF levels in both groups remained stable until day 20 post-wounding when a significant elevation of wound site PDGF levels occurred in the diabetic group. The findings suggest that absence of an initial increase in PDGF may play an important role in poor wound healing observed in diabetic animals. The reduction in PDGF may be related to decreased cellular PDGF production rather than a lack of PDGF-producing cells. Perhaps the diabetic state inhibits cellular PDGF gene expression signaled by wounding or interferes with normal PDGF expression at the wound site.

References (42)

M.C. Robson et al.
Lancet
(1992)
R.L. Brown et al.
J. Surg. Res.
(1994)
J.M. Lepisto et al.
J. Surg. Res.
(1992)
P. Martin et al.
Prog. Growth Factor Res.
(1992)
T.A. Mustoe et al.
Am.J. Surg.
(1989)
O.H. Lowry et al.
J. Biol. Chem.
(1951)
D.K. Yue et al.
Diabetes
(1987)
C.T. Black et al.
J. Surg. Res.
(1989)
I.K. Cohen et al.
R.A.F. Clark et al.

P.M. Lecompte et al.

G.R. Grotendorst et al.

J. Clin. Invest.

(1985)

K.N. Broadley et al.

Biotechnol. Therapeut.

(1989)

G.L. Brown et al.

Plast. Reconstr. Surg.

(1991)

M.C. Robson et al.

Ann. Surg.

(1993)

S.E. Lynch et al.

J. Clin Invest.

(1989)

S.E. Lynch et al.

J. Periodontol.

(1991)

D.G. Greenhalgh et al.

Wound Rep. Regen.

(1993)

D.R. Knighton et al.

Surg. Gynecol. Obstet.

(1990)

S.C. Atri et al.

Surgery

(1990)

Cited by (94)

Revolutionizing diabetic wound healing: Targeted therapeutic strategies based on growth factors
2024, Obesity Medicine
Wound healing in diabetic patients, particularly diabetic wound, poses a substantial challenge compared to typical wounds and can frequently worsen, potentially leading to amputation. Conventional treatments often fall short in effectively healing diabetic wounds and addressing their numerous complications. Growth factors are recognized as pivotal in orchestrating the intricate process of diabetic wound healing. Various growth factors, such as transforming growth factor beta 1, insulin-like growth factor, and vascular endothelial growth factor, assume distinct roles in this healing process. This suggests that therapeutic interventions capable of modulating multiple growth factors to align with the specific needs of wound healing could significantly enhance the treatment of diabetic wounds. Furthermore, some existing treatments have demonstrated the ability to facilitate the healing of diabetic wounds by influencing specific growth factors. The objective of this study was to investigate that the individual contributions of each growth factor in therapeutic strategies, with the aim of stimulating further innovative approaches to diabetes wound care.
Macrophage regulation of angiogenesis in health and disease
2021, Seminars in Cell and Developmental Biology
Citation Excerpt :
By contrast to healthy wounds in which pro-inflammatory macrophages drive vessel sprouting, the increased pro-inflammatory population in diabetic mouse wounds leads to a decrease in pro-angiogenic signals for sprouting (e.g. VEGF [105]). Unsurprisingly, these wounds also have decreased levels of pro-angiogenic signals for vessel maturation (ANG1 [106]) and pericyte recruitment (PDGF [107]), corresponding to key angiogenic processes at later wound repair stages. Furthermore, diabetic mouse wound models also have increased levels of some anti-angiogenic signals, such as ANG2 [108].
Macrophages are primarily known as phagocytic innate immune cells, but are, in fact, highly dynamic multi-taskers that interact with many different tissue types and have regulatory roles in development, homeostasis, tissue repair, and disease. In all of these scenarios angiogenesis is pivotal and macrophages appear to play a key role in guiding both blood vessel sprouting and remodelling wherever that occurs. Recent studies have explored these processes in a diverse range of models utilising the complementary strengths of rodent, fish and tissue culture studies to unravel the mechanisms underlying these interactions and regulatory functions. Here we discuss how macrophages regulate angiogenesis and its resolution as embryonic tissues grow, as well as their parallel and different functions in repairing wounds and in pathologies, with a focus on chronic wounds and cancer.
Hyperbaric oxygen alters intracellular bioenergetics distribution in human dermal fibroblasts
2021, Life Sciences
Citation Excerpt :
The mechanism by which the disease impedes wound healing still remains unclear. Some possible etiologies from previous studies include excess protease activity, decreased growth factor production, or an increase in microbial load [28–30]. Fibroblast cell migration and proliferation play pivotal roles in furthering wound repair by triggering new extracellular matrix synthesis [31].
Hyperbaric oxygen therapy (HBOT), used to promote wound healing, has limited efficacy in many clinical conditions. Wound healing exerts bioenergetic demands on cells that can exceed their intrinsic bioenergetic capacity to proliferate and migrate. The aim of this investigation was to quantify the effects of HBOT on mitochondrial dynamics and bioenergetics functions in cells relevant to wound healing.
High-resolution respirometry and fluorescence microscopy were used to quantify mitochondrial respiration, intermembrane potential, dynamics, including motility, and the intracellular distribution of mitochondrial bioenergetic capacity partitioned into perinuclear and cell peripheral regions in cultured human dermal fibroblasts. Cells were subjected to a range of gas mixtures and hyperbaric pressures, including conditions utilized in clinical care.
Motility was reduced immediately following all HBOT exposures utilized in experiments. Inhomogeneities in intermembrane potential and respiration parameters were produced by different HBOT conditions. The partitioning of ATP-linked respiration was also HBOT-condition dependent. Application of HBOT at common clinical pressure and oxygen conditions resulted in the largest immediate decrement in mitochondrial motility and reductions in ATP-linked respiration in both the cell periphery and perinuclear zones. Aberrations in motility and respiration were also present 6 h after exposure.
HBOT produces intracellular distinctions and inhomogeneities in mitochondrial dynamics and bioenergetics. HBOT as is commonly applied in clinical medicine induced undesirable and persistent alterations in bioenergy function needed to support cell migration and/or proliferation. There may be alternative HBOT parameters that more effectively engender maintenance and adequacy of intracellular bioenergy supply to promote wound healing.
The impact of type 2 diabetes on bone metabolism and growth after spinal fusion
2019, Spine Journal
Some clinical reports suggest diabetes may have a negative effect on spinal fusion outcomes, although no conclusive experimental research has been conducted to investigate the causality, impact, and inherent risks of this growing patient population.
To analyze the hypothesis that type 2 diabetes (T2DM) inhibits the formation of a solid bony union after spinal fusion surgery by altering the local microenvironment at the fusion site through a reduction in growth factors critical for bone formation.
In vivo rodent model of type 2 diabetes.
Twenty control (Sprague Dawley, SD) and 30 diabetic (Zucker Diabetic Sprague Dawley, ZDSD) rats underwent posterolateral and laminar fusion surgery using a tailbone autograft implanted onto the L4/L5 transverse processes. A subset of animals was sacrificed 1-week postsurgery for growth factor analysis. Remaining rats were sacrificed 3-month postsurgery for fusion evaluation via manual palpation, micro-CT, and histology.
There was no significant difference in the manual palpation fusion rate between ZDSD rats and SD control rats. Growth factor assay of fusion site explants at early sacrifice demonstrated PDGF was upregulated in the ZDSD rats. TGFB, IGF, and VEGF were not statistically different between groups. Bone mineral density as determined by micro-CT was significantly lower in ZDSD rats compared to SD controls and was a significant function of HbA1c.
Data generated in this in vivo rat model of T2DM demonstrate that the metabolic dysregulation associated with the diabetic condition negatively impacts the quality and density of the formed fusion mass. Increased measures of diabetic status, as determined by blood glucose and HbA1c, were correlated with decreased quality of formed fusion, highlighting the importance of diabetic status monitoring and regulation to bone health, particularly during bone healing.
T2DM rats demonstrated increased rates of infection, metabolic dysregulation, and a reduction in spinal fusion consolidation. Clinicians should consider these negative effects during preoperative care and treatment of this growing patient population.
Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing
2019, Biomedicine and Pharmacotherapy
Citation Excerpt :
It facilitates synthesis of glycosaminoglycans, proteoglycans and collagen. It acts as a key mediator in the migration and proliferation of fibroblasts, production of granulation tissue proteins and provisional ECM and angiogenesis during the healing process [66]. PDGF and its receptors expression is decreased in diabetic wounds, signifying its role in healing process [67].
Wound management in diabetic patient is of an extreme clinical and social concern. The delayed and impaired healing makes it more critical for research focus. The research on impaired healing process is proceeding hastily evident by new therapeutic approaches other than conventional such as single growth factor, dual growth factor, skin substitutes, cytokine stimulators, cytokine inhibitors, matrix metalloproteinase inhibitors, gene and stem cell therapy, extracellular matrix and angiogenesis stimulators. Although numerous studies are available that support delayed wound healing in diabetes but detailed mechanistic insight including factors involved and their role still needs to be revealed. This review mainly focuses on the molecular cascades of cytokines (with growth factors) and erstwhile factors responsible for delayed wound healing, molecular targets and recent advancements in complete healing and its cure. Present article briefed recent pioneering information on possible molecular targets and treatment strategies including clinical trials to clinicians and researchers working in similar area.
Protective Factors and the Pathogenesis of Complications in Diabetes
2024, Endocrine Reviews

View all citing articles on Scopus

View full text

Platelet-derived growth factor levels in wounds of diabetic rats

Abstract

Lancet

J. Surg. Res.

J. Surg. Res.

Prog. Growth Factor Res.

Am.J. Surg.

J. Biol. Chem.

Diabetes

J. Surg. Res.

J. Clin. Invest.

Biotechnol. Therapeut.

Plast. Reconstr. Surg.

Ann. Surg.

J. Clin Invest.

J. Periodontol.

Wound Rep. Regen.

Surg. Gynecol. Obstet.

Surgery